Download PDF
CC BY-NC-ND 4.0 · Neurology International Open 2018; 02(01): E56-E59
DOI: 10.1055/s-0043-125342
Review
Eigentümer und Copyright ©Georg Thieme Verlag KG 2018

Escalation Strategies in the Treatment of Refractory Myasthenia Gravis

Sarah Hoffmann
1   Klinik für Neurologie, Charité – Universitätsmedizin Berlin
2   NeuroCure Clinical Research Centre (NCRC), Charité – Universitätsmedizin Berlin
,
Andreas Meisel
1   Klinik für Neurologie, Charité – Universitätsmedizin Berlin
2   NeuroCure Clinical Research Centre (NCRC), Charité – Universitätsmedizin Berlin
› Author Affiliations
Further Information

Publication History

Publication Date:
21 February 2018 (online)

   Permissions and Reprints

Abstract

Among all patients with myasthenia gravis (MG), 10 to 15% are considered to be refractory to (expanded) standard treatments. Current international consensus guidelines for the management of myasthenia gravis recommend referral of refractory MG patients to centers with expertise in the treatment of MG and chronic intravenous immunoglobulin therapy or plasmapheresis. Here we briefly summarize current approaches to overcome refractory myasthenia gravis.

Key words

myasthenia gravis - refractory MG - immunosuppression - rituximab - eculizumab
 

  • References

  • 1 Sanders DB, Wolfe GI, Benatar M. et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016; 87: 419-425
    CrossrefPubMedGoogle Scholar
  • 2 Tandan R, Hehir 2nd MK, Waheed W. et al. Rituximab treatment of myasthenia gravis: A systematic review. Muscle Nerve 2017; 56: 185-196
    CrossrefPubMedGoogle Scholar
  • 3 Anderson D, Phan C, Johnston WS. et al. Rituximab in refractory myasthenia gravis: A prospective, open-label study with long-term follow-up. Ann Clin Transl Neurol 2016; 3: 552-555
    CrossrefPubMedGoogle Scholar
  • 4 Iorio R, Damato V, Alboini PE. et al. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol 2015; 262: 1115-1119
    CrossrefPubMedGoogle Scholar
  • 5 Robeson KR, Kumar A, Keung B. et al. Durability of the rituximab response in acetylcholine receptor autoantibody-positive myasthenia gravis. JAMA Neurol 2017; 74: 60-66
    CrossrefPubMedGoogle Scholar
  • 6 Lebrun C, Bourg V, Bresch S. et al. Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis. J Neuroimmunol 2016; 298: 79-81
    CrossrefPubMedGoogle Scholar
  • 7 Afanasiev V, Demeret S, Bolgert F. et al. Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients. Neuromuscul Disord 2017; 27: 251-258
    CrossrefPubMedGoogle Scholar
  • 8 Kanth KM, Solorzano GE, Goldman MD. PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents. Neurol Clin Pract 2016; 6: e17-e19
    CrossrefPubMedGoogle Scholar
  • 9 Braune SA, Wichmann D, von Heinz MC. et al. Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome. Crit Care Med 2013; 41: 1702-1710
    CrossrefPubMedGoogle Scholar
  • 10 Howard Jr. JF, Barohn RJ, Cutter GR. et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve 2013; 48: 76-84
    CrossrefPubMedGoogle Scholar
  • 11 Howard Jr. JF, Utsugisawa K, Benatar M. et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 2017; 16: 976-986
    CrossrefPubMedGoogle Scholar
  • 12 Ärztlicher Beirat der Deutschen Myasthenie Gesellschaft (DMG). Ärztlicher Beirat zu Eculizumab-Therapie [online]. Available at: http://www.dmg-online.de/aerztlicher-beirat-zu-eculizumab-therapie/Accessed 18.12.2017
    PubMed
  • 13 De Feo LG, Schottlender J, Martelli NA. et al. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve 2002; 26: 31-36
    CrossrefPubMedGoogle Scholar
  • 14 Drachman DB, Adams RN, Hu R. et al. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci 2008; 1132: 305-314
    CrossrefPubMedGoogle Scholar
  • 15 Gladstone DE, Brannagan 3rd TH, Schwartzman RJ. et al. High dose cyclophosphamide for severe refractory myasthenia gravis. J Neurol Neurosurg Psychiatry 2004; 75: 789-791
    PubMedGoogle Scholar
  • 16 Buzzard KA, Meyer NJ, Hardy TA. et al. Induction intravenous cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis. Muscle Nerve 2015; 52: 204-210
    CrossrefPubMedGoogle Scholar
  • 17 Nagappa M, Netravathi M, Taly AB. et al. Long-term efficacy and limitations of cyclophosphamide in myasthenia gravis. J Clin Neurosci 2014; 21: 1909-1914
    CrossrefPubMedGoogle Scholar
  • 18 Bryant A, Atkins H, Pringle CE. et al. Myasthenia gravis treated with autologous hematopoietic stem cell transplantation. JAMA Neurol 2016; 73: 652-658
    CrossrefPubMedGoogle Scholar
  • 19 Smith CI, Hammarstrom L, Lefvert AK. Bone-marrow grafting induces acetylcholine receptor antibody formation. Lancet 1985; 1: 978
    PubMedGoogle Scholar
  • 20 Tsutsumi Y, Kamiishi T, Kikuchi R. et al. Myasthenia gravis after allogeneic bone marrow transplantation: A case report and literature review. Hematol Oncol Stem Cell Ther 2017; DOI: 10.1016/j.hemonc.2017.04.001.
    CrossrefPubMedGoogle Scholar